Antibe Therapeutics Inc (CVE:ATE) – Analysts at Zacks Investment Research lowered their FY2019 earnings per share (EPS) estimates for shares of Antibe Therapeutics in a research report issued to clients and investors on Tuesday. Zacks Investment Research analyst D. Bautz now anticipates that the company will post earnings of ($0.02) per share for the year, down from their prior forecast of ($0.01).

WARNING: “FY2019 Earnings Estimate for Antibe Therapeutics Inc Issued By Zacks Investment Research (ATE)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/08/fy2019-earnings-estimate-for-antibe-therapeutics-inc-issued-by-zacks-investment-research-ate.html.

About Antibe Therapeutics

Antibe Therapeutics Inc is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company’s segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

Receive News & Ratings for Antibe Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.